American Thoracic Society 2023
May 30, 2023
ATS 2023 Updates: AD109’s Potential as the First Oral Medication for Obstructive Sleep Apnea (OSA)
Apnimed’s AD109 has the potential to be the first oral pharmaceutical drug that remedies both, the primary cause of OSA, nocturnal airway obstruction, and the daytime symptoms of OSA, such as fatigue. The dual mode of action of AD109 leads to upper airway dilatation as well as enhanced breathing and oxygen...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
